Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

Miró, José M.; Montejo, Miguel; Castells, Lluı́s; Rafecas, Antoni; Moreno, Santiago; Agüero, Fernando; Abradelo, M.; Miralles, Pilar; Torre‐Cisneros, Julián; Pedreira, José; Cordero, Elisa; Rosa, Gloria de la; Moyano, Berta; Moreno, Asunción; Pérez, Iñaki; Rimola, Antoni

doi:10.1111/j.1600-6143.2012.04028.x

Cited by 132 publications

(179 citation statements)

References 32 publications

Supporting

Mentioning

167

Contrasting

Order By: Relevance

“…133 Two prospective studies have shown lower patient survival and higher incidence of acute cellular rejection in HCV and HIV coinfected cohort compared to HCV monoinfected patients. 134,135 FCH and sepsis are the leading causes of death in HCV and HIV coinfected patients. [136][137][138] With the availability of DAA for the treatment of recurrent HCV following liver transplantation, SVR rates have improved in HCV and HIV coinfected patients.…”

Section: Management Of Hcv In Hiv Coinfectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Management Of Hcv In Hiv Coinfectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Endomyocardial biopsies are performed as in every other transplant patient following local protocols, with a minimum of six biopsies during the first 6 months after transplant and subsequently if clinically indicated. Findings from liver and kidney transplant cohorts seem to confirm that HIVinfected persons are significantly more likely to develop acute rejection than recipients without HIV infection (8,9,33). In fact, most HT recipients with HIV infection listed in Table 2 had rejection episodes.…”

Section: Immunosuppression and Rejectionmentioning

confidence: 90%

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

Agüero

Castel

Cocchi

et al. 2016

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

“…Among Spanish patients with HIV and HCV co-infection, liver transplantation outcomes were similar to HIV-negative patients who underwent similar surgery. 87 …”

Section: Hepatocellular Cancermentioning

confidence: 99%

Cancer screening in women living with HIV infection

Aboulafia

2017

Womens Health (Lond Engl)

View full text Add to dashboard Cite

The number of women living with HIV continues to increase. Thirty years into the AIDS epidemic, we now expect those with access to highly active antiretroviral to survive into their seventh decade of life or beyond. Increasingly, the focus of HIV care is evolving from preventing opportunistic infections and treating AIDS-defining malignancies to strategies that promote longevity. This holistic approach to care includes detection of malignancies that are associated with certain viral infections, with chronic inflammation, and with lifestyle choices. The decision to screen an HIV-infected women for cancer should include an appreciation of the individualized risk of cancer, her life expectancy, and an attempt to balance these concerns with the harms and benefits associated with specific cancer screening tests and their potential outcome. Here, we review cancer screening strategies for women living with HIV/AIDS with a focus on cancers of the lung, breast, cervix, anus, and liver.

show abstract

Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

Cited by 132 publications

References 32 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

Cancer screening in women living with HIV infection

Contact Info

Product

Resources

About